Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Grants Breakthrough Status to ETX101 Gene Therapy for Dravet Syndrome
The FDA grants breakthrough therapy designation to ETX101, an experimental one-time gene therapy for Dravet syndrome by Encoded Therapeutics. Explore clinical data and mechanism.
Gene Therapy for Chronic Pain: Targeted CNS Circuits Without Addiction
A novel gene therapy approach targets pain circuits in the brain using AI-driven behavior tracking. A non-addictive alternative to opioids for chronic pain relief.
FDA Issues New Guidance on Bayesian Methodologies for Clinical Trials
Explore the FDA's latest draft guidance on using Bayesian statistics in clinical trials. Learn how these methods reduce costs, timelines, and support rare disease research.
Syntopia: Breakthrough Microfluidic Platform for Drug Screening
Syntopia, a SYNEBIO spin-off, launches a pump-free microfluidic platform for 3D cell culture and high-throughput drug screening, reducing animal testing.
FDA Issues Urgent Recall: Illegal Drugs Found in Modern Warrior Supplements
FDA recall alert: Modern Warrior Ready supplements found to contain tianeptine, 1,4-DMAA, and aniracetam. Critical health risks identified for consumers.
Nvidia & Eli Lilly to Invest $1B in AI Medical Research Lab
Nvidia and Eli Lilly partner to open a $1B AI research lab in South San Francisco. Explore how Rubin chips, BioNeMo, and digital twins will redefine drug discovery.
Eli Lilly Acquires Ventyx for $1.2B: Expanding in NLRP3 Space
Eli Lilly diversifies its pipeline with the $1.2bn acquisition of Ventyx Biosciences, targeting NLRP3 inhibitors for cardiometabolic and neurodegenerative diseases.
Clinical Trials: The Engine of Medical Progress & Innovation
From James Lind to modern decentralized models: explore how clinical trials drive the drug development process, regulatory agility, and global public health.
FDA Approves New 2g Fibryga Formulation for AFD
Octapharma receives FDA approval for a new 2g Fibryga kit. Discover how this human plasma-derived fibrinogen concentrate improves haemostasis in urgent care.
Iza-Bren (EGFR×HER3 ADC): New Precision Cancer Treatment
Learn about Iza-Bren (BL-B01D1), a breakthrough bispecific ADC by SystImmune & BMS targeting EGFR and HER3 for lung and nasopharyngeal cancer treatment.
Novel Small Molecule Inhibitors in Endometrial Cancer: Phase 2b Results
Prexasertib (ACR-368) shows 67% ORR in serous endometrial cancer. Explore the latest Phase 2b trial data, AP3 platform insights, and ACR-2316 development.
VectorY VTx-002 Earns FDA Fast Track for ALS Therapy
VectorY Therapeutics receives FDA Fast Track status for VTx-002, a vectorized antibody targeting TDP-43 to treat Amyotrophic Lateral Sclerosis (ALS).
9
10
11
12
13
14
15
16
17
